Skip to Content
Merck
CN

382177

HDAC Inhibitor XIX, Compound 2

The HDAC Inhibitor XIX, Compound 2, also referenced under CAS 6953-61-3, controls the biological activity of HDAC. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

Synonym(s):

HDAC Inhibitor XIX, Compound 2, 1-Naphthohydroxamic Acid, N-Hydroxynaphthalene-1-carboxamide, Histone Deacetylase Inhibitor XIX

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C11H9NO2
CAS Number:
Molecular Weight:
187.19
UNSPSC Code:
12352200
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

form

solid

InChI

1S/C11H9NO2/c13-11(12-14)10-7-3-5-8-4-1-2-6-9(8)10/h1-7,14H,(H,12,13)

InChI key

JRZGPWOEHDOVMC-UHFFFAOYSA-N

assay

≥97% (HPLC)

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

white

solubility

DMSO: 50 mg/mL

shipped in

ambient

Quality Level

General description

A cell-permeable aryl-hydroxamate compound that selectively inhibits the activity of HDAC8 (IC50 = 14 µM) over class I HDAC1 and class II HDAC6 (IC50 >100 µM) without affecting the overall H4 acetylation level in BE(2)-C cultures even at concentrations as high as 20 µM. HDAC8 downregulation by either Compound 2 (10 to 40 µM) or siRNA in neuroblastoma cultures is reported to result in growth inhibition accompanied by neurite-like morphological changes. Compound 2 effectively enhances tubulin acetylation in both HeLa and HEK 293 cultures, indicating that alternative cellular enzyme(s) other than HDAC6 can be targeted for regulating tubulin acetylation.

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Other Notes

Oehme, I., et al. 2009. Expert Opin. Investig. Drugs18, 1605.
Oehme, I., et al. 2009. Clin. Cancer Res.15, 91.
KrennHrubec, K., et al. 2007. Bioorg. Med. Chem. Lett.17, 2874.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Related Content

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service